Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Kalvista Pharmaceuticals Inc's Business Segments
Kalvista Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Product
Total Revenue
$ 41
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product95.8%
- Partnership and Other Revenue4.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 39 | 95.8% |
| Partnership and Other Revenue | $ 2 | 4.2% |
Revenue by Product & Service Category - FY
- Product95.8%
- Partnership and Other Revenue4.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 39 | 95.8% |
| Partnership and Other Revenue | $ 2 | 4.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product95.8%
- Partnership and Other Revenue4.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 39 | 95.8% |
| Partnership and Other Revenue | $ 2 | 4.2% |
Description of Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule protease inhibitors. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
KalVista Pharmaceuticals specializes in the development of novel therapies for diseases with significant unmet medical needs, particularly in the areas of hereditary angioedema (HAE) and diabetic macular edema (DME). The company's mission is to improve the lives of patients suffering from these debilitating conditions by developing innovative and effective treatments.
One of the key therapeutic focuses of KalVista Pharmaceuticals is hereditary angioedema (HAE), a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body. HAE affects an estimated 1 in 10,000 to 1 in 50,000 individuals worldwide. The company is developing oral HAE therapies that offer a more convenient and patient-friendly alternative to current injectable treatments.
In addition to HAE, KalVista Pharmaceuticals is actively engaged in the development of treatments for diabetic macular edema (DME), a leading cause of vision loss in patients with diabetes. DME is characterized by fluid accumulation in the macula, which leads to blurred vision and potential blindness. The company is developing intravitreal DME therapies that aim to reduce edema and improve visual function in affected patients.
KalVista Pharmaceuticals leverages its expertise in protease inhibitors to design and develop potent and selective small molecules that target specific proteases involved in the pathogenesis of HAE and DME. These proteases play a critical role in the generation of bradykinin, a protein that causes blood vessels to dilate, leading to the characteristic symptoms of HAE and the leakage of fluid into the macula in DME.
The company's drug development pipeline includes several promising candidates, including KVD824, a highly selective inhibitor of plasma kallikrein for the treatment of HAE, and KVD001, a potent inhibitor of plasma kallikrein for the treatment of DME. KalVista Pharmaceuticals conducts rigorous preclinical and clinical studies to evaluate the safety, efficacy, and tolerability of its drug candidates, with the ultimate goal of obtaining regulatory approval and bringing these therapies to market.
Furthermore, KalVista Pharmaceuticals actively seeks strategic partnerships and collaborations with pharmaceutical companies and other research organizations to accelerate the development and commercialization of its pipeline. The company has forged partnerships with renowned institutions such as the University of Cambridge and has received financial support from prestigious organizations like the Cystic Fibrosis Foundation Therapeutics Inc. (CFFT).
In summary, KalVista Pharmaceuticals is a biopharmaceutical company dedicated to advancing the field of protease inhibition therapies for the treatment of hereditary angioedema and diabetic macular edema. With a robust pipeline of innovative drug candidates and a commitment to improving patient outcomes, the company is poised to make a significant impact on the lives of individuals suffering from these challenging conditions.
KalVista Pharmaceuticals specializes in the development of novel therapies for diseases with significant unmet medical needs, particularly in the areas of hereditary angioedema (HAE) and diabetic macular edema (DME). The company's mission is to improve the lives of patients suffering from these debilitating conditions by developing innovative and effective treatments.
One of the key therapeutic focuses of KalVista Pharmaceuticals is hereditary angioedema (HAE), a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body. HAE affects an estimated 1 in 10,000 to 1 in 50,000 individuals worldwide. The company is developing oral HAE therapies that offer a more convenient and patient-friendly alternative to current injectable treatments.
In addition to HAE, KalVista Pharmaceuticals is actively engaged in the development of treatments for diabetic macular edema (DME), a leading cause of vision loss in patients with diabetes. DME is characterized by fluid accumulation in the macula, which leads to blurred vision and potential blindness. The company is developing intravitreal DME therapies that aim to reduce edema and improve visual function in affected patients.
KalVista Pharmaceuticals leverages its expertise in protease inhibitors to design and develop potent and selective small molecules that target specific proteases involved in the pathogenesis of HAE and DME. These proteases play a critical role in the generation of bradykinin, a protein that causes blood vessels to dilate, leading to the characteristic symptoms of HAE and the leakage of fluid into the macula in DME.
The company's drug development pipeline includes several promising candidates, including KVD824, a highly selective inhibitor of plasma kallikrein for the treatment of HAE, and KVD001, a potent inhibitor of plasma kallikrein for the treatment of DME. KalVista Pharmaceuticals conducts rigorous preclinical and clinical studies to evaluate the safety, efficacy, and tolerability of its drug candidates, with the ultimate goal of obtaining regulatory approval and bringing these therapies to market.
Furthermore, KalVista Pharmaceuticals actively seeks strategic partnerships and collaborations with pharmaceutical companies and other research organizations to accelerate the development and commercialization of its pipeline. The company has forged partnerships with renowned institutions such as the University of Cambridge and has received financial support from prestigious organizations like the Cystic Fibrosis Foundation Therapeutics Inc. (CFFT).
In summary, KalVista Pharmaceuticals is a biopharmaceutical company dedicated to advancing the field of protease inhibition therapies for the treatment of hereditary angioedema and diabetic macular edema. With a robust pipeline of innovative drug candidates and a commitment to improving patient outcomes, the company is poised to make a significant impact on the lives of individuals suffering from these challenging conditions.
Kalvista Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for diseases that involve protease dysregulation. The company primarily focuses on the development of therapies for eye diseases and hereditary angioedema. Below is a comprehensive overview of the segments, products, and services that Kalvista Pharmaceuticals Inc. offers.
Segments
1. Ophthalmology: Kalvista is actively engaged in the development of treatments for various eye diseases, particularly those associated with retinal conditions. The main focus is on diseases like diabetic macular edema (DME) and other related retinal disorders that require novel treatments.
2. Hereditary Angioedema (HAE): This segment focuses on developing products for patients suffering from HAE, a genetic condition that leads to recurrent episodes of severe swelling. Kalvista is exploring innovative therapies aimed at managing and alleviating the symptoms associated with this condition.
3. Research and Development (R&D): The company invests a significant portion of its resources in R&D to discover new drug candidates and to advance existing candidates through clinical trials. This segment focuses on drug discovery, preclinical and clinical evaluation, regulatory submission, and post-marketing studies.
Products and Services
1. KVD824: This is a product candidate designed for the treatment of HAE. It is an oral formulation that aims to target the bradykinin pathway, which is often implicated in HAE episodes. KVD824 is undergoing clinical testing to demonstrate its safety and efficacy in managing HAE symptoms.
2. KVD001: This candidate represents Kalvistas innovative approach to treating diabetic macular edema (DME). KVD001 is designed as an intravitreal injection to deliver a potent serine protease to help reduce the accumulation of fluid under the retina, which can impair vision.
3. Combination therapies: There’s a focus on evaluating combination therapies that include potential synergistic effects of Kalvistas offerings with existing treatment modalities. This can enhance the effectiveness in managing both HAE and retinal diseases.
Research Collaborations and Partnerships
In addition to developing its proprietary therapies, Kalvista Pharmaceuticals frequently engages in collaborations with academic institutions, research organizations, and other pharmaceutical companies. These collaborations often aim to leverage expertise, share resources, or co-develop specialized treatments for complex diseases.
Drug Development Services
Kalvista may offer consultation and partnership opportunities for other pharmaceutical companies or research institutions looking to develop protease inhibitors or related therapeutic approaches. This can involve:
- Preclinical Development: Supporting early-stage drug development by providing expertise in study design, execution, and data analysis.
- Clinical Development: Offering services that can include protocol development, patient recruitment strategies, and clinical trial management.
- Regulatory Affairs: Guidance on navigating the regulatory landscape for drug approval, including document preparation, submissions to agencies like the FDA, and compliance with regulatory requirements.
Intellectual Property
Kalvista places a strong emphasis on protecting its innovations and has developed a robust intellectual property portfolio related to its product candidates. This strategic focus on patents supports its competitive advantage in the marketplace and underscores its commitment to bringing novel therapeutics to patients.
Commitment to Patients
Kalvista is dedicated to improving the quality of life for patients suffering from serious health conditions. This commitment is reflected not only in the innovative drugs being developed but also in the patient-centric approach they adopt in their clinical trials—ensuring that patient perspectives are considered in the development process.
In summary, Kalvista Pharmaceuticals Inc. operates in specialized segments with an emphasis on innovative therapies for ocular diseases and hereditary angioedema. With a pipeline of promising drug candidates, partnerships for research collaboration, and a focus on rigorous R&D, the company is positioned to contribute significantly to the field of biopharmaceuticals.
Segments
1. Ophthalmology: Kalvista is actively engaged in the development of treatments for various eye diseases, particularly those associated with retinal conditions. The main focus is on diseases like diabetic macular edema (DME) and other related retinal disorders that require novel treatments.
2. Hereditary Angioedema (HAE): This segment focuses on developing products for patients suffering from HAE, a genetic condition that leads to recurrent episodes of severe swelling. Kalvista is exploring innovative therapies aimed at managing and alleviating the symptoms associated with this condition.
3. Research and Development (R&D): The company invests a significant portion of its resources in R&D to discover new drug candidates and to advance existing candidates through clinical trials. This segment focuses on drug discovery, preclinical and clinical evaluation, regulatory submission, and post-marketing studies.
Products and Services
1. KVD824: This is a product candidate designed for the treatment of HAE. It is an oral formulation that aims to target the bradykinin pathway, which is often implicated in HAE episodes. KVD824 is undergoing clinical testing to demonstrate its safety and efficacy in managing HAE symptoms.
2. KVD001: This candidate represents Kalvistas innovative approach to treating diabetic macular edema (DME). KVD001 is designed as an intravitreal injection to deliver a potent serine protease to help reduce the accumulation of fluid under the retina, which can impair vision.
3. Combination therapies: There’s a focus on evaluating combination therapies that include potential synergistic effects of Kalvistas offerings with existing treatment modalities. This can enhance the effectiveness in managing both HAE and retinal diseases.
Research Collaborations and Partnerships
In addition to developing its proprietary therapies, Kalvista Pharmaceuticals frequently engages in collaborations with academic institutions, research organizations, and other pharmaceutical companies. These collaborations often aim to leverage expertise, share resources, or co-develop specialized treatments for complex diseases.
Drug Development Services
Kalvista may offer consultation and partnership opportunities for other pharmaceutical companies or research institutions looking to develop protease inhibitors or related therapeutic approaches. This can involve:
- Preclinical Development: Supporting early-stage drug development by providing expertise in study design, execution, and data analysis.
- Clinical Development: Offering services that can include protocol development, patient recruitment strategies, and clinical trial management.
- Regulatory Affairs: Guidance on navigating the regulatory landscape for drug approval, including document preparation, submissions to agencies like the FDA, and compliance with regulatory requirements.
Intellectual Property
Kalvista places a strong emphasis on protecting its innovations and has developed a robust intellectual property portfolio related to its product candidates. This strategic focus on patents supports its competitive advantage in the marketplace and underscores its commitment to bringing novel therapeutics to patients.
Commitment to Patients
Kalvista is dedicated to improving the quality of life for patients suffering from serious health conditions. This commitment is reflected not only in the innovative drugs being developed but also in the patient-centric approach they adopt in their clinical trials—ensuring that patient perspectives are considered in the development process.
In summary, Kalvista Pharmaceuticals Inc. operates in specialized segments with an emphasis on innovative therapies for ocular diseases and hereditary angioedema. With a pipeline of promising drug candidates, partnerships for research collaboration, and a focus on rigorous R&D, the company is positioned to contribute significantly to the field of biopharmaceuticals.